In a meta-analysis, UDCA treatment showed a significant effect on ALT and GGT in patients with liver disease, but in studies including only NAFLD or NASH patients, no significance was shown. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.